02165nas a2200181 4500000000100000008004100001260004600042653004400088653001600132100001000148700001200158700001100170245009500181856013600276490000800412520154900420022001401969 2025 d bOvid Technologies (Wolters Kluwer Health)10aDapsone hypersensitivity syndrome (DHS)10aNon-Leprosy1 aZhu H1 aJiang S1 aSong G00aNon-leprosy related dapsone hypersensitivity syndrome: A case report and literature review uhttps://journals.lww.com/md-journal/fulltext/2025/07040/non_leprosy_related_dapsone_hypersensitivity.66.aspx?context=latestarticles0 v1043 a
Rationale: Dapsone is used for treating infectious and immunological disorders, but it may cause dapsone hypersensitivity syndrome (DHS), a serious concern for medical staff. However, in non-leprotic patients, the manifestations of DHS can be atypical and various, leading to diagnostic challenges and potential delays in treatment initiation, which requires attention.
Patient concerns: A 17-year-old Chinese male developed DHS after 3-week dapsone treatment for vasculitis, showing the risk of dapsone use in young patients.
Diagnosis: DHS symptoms include fever, rash, and lymphadenopathy, which can be life-threatening. Diagnosis for this patient was based on symptom recognition, medical history review, physical examination, and the link between dapsone intake and symptom onset.
Interventions: Once diagnosed, dapsone was withdrawn immediately. Corticosteroids were given to reduce inflammation, and antipyretics and anti-histamines were used for symptom relief.
Outcomes: After treatment, the patient improved. Fever subsided quickly, the rash resolved in a week, and lymphadenopathy shrank. Follow-up showed full recovery with no symptom recurrence.
Lessons: This report details a case and reviews published cases of DHS. Summarizing their features aims to improve diagnostic accuracy and management strategies, thus helping healthcare providers handle similar cases better.
a1536-5964